Tagged with DIA

China The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as well as Bioduro and Sundio’s merger to create one of the largest CRDMOs with operations in China and the US.…

India The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands to grow by between 12 and 14 percent in the next three years, with exports predicted to grow by eight to 14 percent, according to a recent KPMG report.   The…

Diagnostics Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their offerings through R&D.  Cho also compares the challenges of the Chinese market with the potential in the Indian market and offers his opinion on the role of diagnostics in post Covid-19 healthcare.   There is…

Precision Medicine With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region must be addressed effectively, quickly and comprehensively. Who better to accomplish that than the Asian companies on the ground, closest…

Belgium Carl Laurent, managing director and CEO of Siemens Healthineers BeLux, sits down with PharmaBoardroom to explain Siemens Healthineers’ footprint and impact in Belgium and Luxembourg, the importance of appreciating diagnostics as a means of cost reduction in healthcare, and the need to ensure access to the latest medtech innovations.  …

Belgium Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives in Belgium, and the importance of multi-stakeholder collaboration to raise awareness and education around diabetes.   We have a long-term…

Roche Swiss giant Roche tops Pharmaceutical Executive’s 2020 list of the world’s biggest pharma companies, up from second place in 2019 and third in 2018. Though its best-selling drugs are soon to face biosimilar competition, Roche’s diverse portfolio has ensured that it can continue to drive future sales growth. The firm…

Cell & Gene Therapy The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s quest for knowledge, costing USD three billion across 13 years. But even after nearly two decades, we have barely scratched…

Belgium Alexander Alonso, general manager of medtech giant BD’s operations in Belgium, the Netherlands, and Luxembourg outlines the company’s extensive footprint in the region, how it has rapidly mobilised in the fight against COVID-19, and the market access situation for innovative medtech solutions in Belgium today.   In Benelux there is…

India Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials thanks to international partnerships and financial backing.    The Indian companies currently at the forefront of COVID-19 vaccine development are…

Korea Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian patients, explores the company’s expansion plans into China, Japan, and Southeast Asia, and the synergies in their partnerships with big…

Hong Kong Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong sheds light on the Asian diagnostics market and unveils his strategy to expand Xcelom’s offering across Asia.   Our pursuit…